Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA

Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA

Submitted by admin on February 13, 2020 - 11:29pm
Source: 
Motley Fool
News Tags: 
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
Headline: 
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
snippet: 

On Thursday, Seattle Genetics (NASDAQ: SGEN) shared some good news regarding an experimental breast cancer drug called tucatinib. The U.S. Food and Drug Administration (FDA) will give tucatinib's new drug application a priority review.

Do Not Allow Advertisers to Use My Personal information